Pharma & Biotech

For emerging biotechnology firms, the relentless focus on clinical progress often defines investor sentiment. Eupraxia Pharmaceuticals, operating in the small-cap...

FutureGen Industries has announced the successful completion of several divestments within its healthcare portfolio, generating substantial capital gains. The proceeds...

Investor focus is firmly on BioNTech as the biotech firm prepares to release its full-year 2025 financial results this coming...

Following prominent presentations at recent major healthcare conferences, the clinical progress of Olema Pharmaceuticals has captured significant market attention. The...

Investors in Spero Therapeutics are bracing for a pivotal period, with two key events poised to shape the biopharmaceutical company's...

The dissolution of InVivo Therapeutics Holdings is now in its concluding phase. The company’s operations, along with all its research...

The stock of Greenwich Lifesciences Inc finds itself in a holding pattern. In the absence of concrete news regarding fresh...

The coming weeks represent a critical juncture for Replimune Group Inc., with a key regulatory decision and a series of...

Engene's management team is preparing for a critical series of presentations that will place its clinical development program under the...

Recent financial disclosures from leading companies have prompted a strategic shift across the medical technology sector. The focus is now...